Nicotinamide in dermatology and photoprotection

SKINmed

Volumn 9, Issue 6, 2011, Pages 360-365

  Surjana, Devita ^a   Damian, Diona L ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b MELANOMA INSTITUTE AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE; RADIOPROTECTIVE AGENT; VITAMIN B COMPLEX;

DERMATOLOGY; HUMAN; INTRADERMAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; REVIEW; SKIN DISEASE; SKIN TUMOR; STANDARD;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; DERMATOLOGY; HUMANS; NIACINAMIDE; RADIATION-PROTECTIVE AGENTS; SKIN DISEASES; SKIN NEOPLASMS; VITAMIN B COMPLEX;

EID: 84856601143     PISSN: 15409740     EISSN: 17517125     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Jacob RA. Niacin. In: Bowman BA, Rusell RM, eds. Present Knowledge in Nutrition. 8th ed. Washington DC: ILSI Press; 2001:199–206.
2. Niren NM. Pharmacologic doses of nicotinamide in the treatment of inflammatory skin conditions: a review. Cutis. 2006;11(1 suppl):11–16.
3. Visalli N, Cavallo MG, Signore A, et al. A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI). Diabetes Metab Res Rev. 1999;15:181–185.
4. Knip M, Douek IF, Moore WP, et al. Safety of high-dose nicotinamide: a review. Diabetologia. 2000;43:1337–1345.
5. Hankes LV. Nicotinic acid and nicotinamide. In: Machelin LJ, ed. Handbook of Vitamins. New York, NY: Marcel Dekker; 1984:329–377.
6. Final report of the safety assessment of niacinamide and niacin. Int J Toxicol. 2005;24:1–31.
7. Toth B. Lack of carcinogenicity of nicotinamide and isonicotinamide following lifelong adminstration to mice. Oncology. 1983;40:72–75.
8. Drugdex Drug Evaluations. Niacinamide. In: Klasco R, ed. DrugDex(R) System: Thomsom Micromedex. Colorado: Greenwood Village; 2006.
9. Jacobson EL, Shieh WM, Huang AC. Mapping the role of NAD metabolism in prevention and treatment of carcinogenesis. Molecular and Cellular Biochemistry. 1999;193:69–74.
10. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002;54:375–429.
11. Ungerstedt JS, Blomback M, Soderstrom T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol. 2003;131:48–52.
12. Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1995;130:753–758.
13. Honl BA, Elston DM. Autoimmune bullous eruption localized to a breast reconstruction response to niacinamide. Cutis. 1998;62:85–86.
14. Iraji F, Banan L. The efficacy of nicotinamide gel 4% as an adjuvant therapy in the treatment of cutaneous erosions of pemphigus vulgaris. Dermatol Ther. 2010;23:308–311.
15. Daniel J, Marechal Y, Van Gool F, Andris F, Leo O. Nicotinamide inhibits B lymphocyte activation by disrupting MAPK signal transduction. Biochem Pharmacol. 2007;73:831–842.
16. Niren NM, Torok HM. The nicomide improvement in clinical outcomes study (NICOS): results of an 8-week trial. Cutis. 2006;77(suppl 1):17–28.
17. Shalita AR, Smith JG, Parish LC, Sofman MS, Chalker DK. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne-vulgaris. Int J Dermatol. 1995;34:434–437.
18. Weltert Y, Chartier S, Gibaud C, et al. Double-blind clinical evaluation of the efficacy of nicotinamide gel versus 4% erythromycin gel in the treatment of moderate acne in predominantly inflammatory component. Les Nouvelles Dermatologiques. 2004;23:385–394.
19. Grange PA, Raingeaud J, Calvez V, Dupin N. Nicotinamide_ inhibits propionibacterium acnes-induced IL-8 production in keratinocytes through the NF-KB and MAPK pathways. J Dermatol Sci. 2009;56:106–112.
20. Surjana D, Halliday GM, Damian DL. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. J Nucleic Acids. 2010. Jul 25; pii: 157591.
21. Draelos ZD, Matsubara A, Smiles K. The effect of 2% niacinamide on facial sebum production. J Cosmet Laser Ther. 2006;8:96–101.
22. Bissett D. Topical niacinamide and barrier enhancement. Cutis. 2002;70:8–12.
23. Tanno O, Ota Y, Kitamura N, Katsube T, Inoue S. Nicotinamide increases biosynthesis of ceramides as well as other stratrum corneum lipids to improve the epidermal permeability barrier. Br J Dermatol. 2000;143:524–531.
24. Soma Y, Kashima M, Imaizumi A, et al. Moisturizing effects of topical nicotinamide on atopic dry skin. Int J Dermatol. 2005;44:197–202.
25. Draelos ZD, Ertel K, Berge C. Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea. Cutis. 2005;76:135–141.
26. Song XZ, Xu A, Pan W, et al. Nicotinamide attenuates aquaporin 3 overexpression induced by retinoic acid through inhibition of EGFR/ERK in cultured human skin keratinocytes. Int J Mol Med. 2008;22:229–236.
27. Bissett DL, Oblong JE, Berge CA. Niacinamide: a B vitamin that improves aging facial skin appearance. Dermatol Surg. 2005;31(7 pt 2):860–865; discussion 865.
28. Kawada A, Konishi N, Oiso N, Kawara S, Date A. Evaluation of anti-wrinkle effects of a novel cosmetic containing niacinamide. J Dermatol. 2008;35:637–642.
29. Hakozaki T, Minwalla L, Zhuang J, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002;147:20–31.
30. Halliday GM. Inflammation, gene mutation and photoimmunosuppression in response to UVR-induced oxidative damage contributes to photocarcinogenesis. Mutat Res. 2005;571:107–120.
31. Gensler HL. Prevention of photoimmunosuppression and photocarcinogenesis by topical nicotinamide. Nutr Cancer. 1997;29:157–162.
32. Gensler HL, Williams T, Huang AC, Jacobson EL. Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice. Nutr Cancer. 1999;34:36–41.
33. Jacobson EL, Giacomoni PU, Roberts MJ, Wondrak GT, Jacobson MK. Optimizing the energy status of skin cells during solar radiation. J Photochem Photobiol B. 2001;63:141–147.
34. Park J, Halliday GM, Surjana D, Damian DL. Nicotinamide prevents ultraviolet radiation-induced cellular energy loss. Photochem Photobiol. 2010;86:942–948.
35. Farkas B, Magyarlaki M, Csete B, et al. Reduction of acute photodamage in skin by topical application of a novel PARP inhibitor. Biochem Pharmacol. 2002;63:921–932.
36. Sivapirabu G, Yiasemides E, Halliday GM, Park J, Damian DL. Topical nicotinamide modulates cellular energy metabolism and provides broad-spectrum protection against ultraviolet radiation-induced immunosuppression in humans Br J Dermatol. 2009;161:1357–1364.
37. Damian DL, Patterson CRS, Stapelberg M, et al. Ultraviolet radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. J Invest Dermatol. 2008;128:447–454.
38. Yiasemides E, Sivapirabu G, Halliday GM, Park J, Damian DL. Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans. Carcinogenesis. 2009;30:101–105.
39. Poon TS, Barnetson RS, Halliday GM. Prevention of immunosuppression by sunscreens in humans is unrelated to protection from erythema and dependent on protection from ultraviolet A in the face of constant ultraviolet B protection. J Invest Dermatol. 2003;121:184–190.
40. Moloney F, Vestergaard M, Radojkovic B, Damian D. Randomized, double-blinded, placebo controlled study to assess the effect of topical 1% nicotinamide on actinic keratoses. Br J Dermatol. 2010;162:1138–1139.